Loading stock data…
Kalaris Therapeutics, Inc. (KLRS)
$4.21-0.10 (-2.43%)
Market ClosedLast close Jun 29
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kalaris Therapeutics, Inc. in the Healthcare sector is trading at $4.21 with a market capitalization of $112M. Wall Street consensus targets $18.71 (7 analysts), implying a +344.0% move over the next 12 months. The stock is currently 65% below its 52-week high of $11.88, remaining 36.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +344.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$11.83M↓ | -$10.80M↑ | -$12.74M↓ | -$12.26M↓ | -$10.35M |
| Net Income | -$10.86M↓ | -$10.00M↑ | -$11.89M↓ | -$11.35M↓ | -$10.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$112.30M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-64.32%
Volume
Today's trading volume
122,078
Recent News
Starbucks upgraded, Doximity downgraded: Wall Street's top analyst calls
Starbucks upgraded, Doximity downgraded: Wall Street's top analyst calls
We Think Kalaris Therapeutics (NASDAQ:KLRS) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Kalaris Therapeutics, Inc.'s (NASDAQ:KLRS) biggest owners are private equity firms who got richer after stock soared 24% last week
Key Insights Kalaris Therapeutics' significant private equity firms ownership suggests that the key decisions are...
Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know
Kalaris Therapeutics Inc. (KLRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).